Trial · NCT07015346
Adhesion and Safety of Rotigexole Compared to Neupro®
NCT07015346, Not applicable, Not yet recruiting, Eva Pharma
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Adhesion and Safety of Rotigexole Compared to Neupro®. Trials, record NCT07015346. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07015346
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Adhesion and Safety of Rotigexole Compared to Neupro®
- NCT number
- NCT07015346
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Eva Pharma
- Conditions
- Idiopathic Parkinson Disease
- Interventions
- Rotigexole 8 mg, Neupro ® 8 mg
- First posted
- 2025-06-11
- Last updated
- 2025-08-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The cumulative mean percentage adhesion of the transdermal patch over the 24-hour dosing interval for two treatment periods, compared between Rotigexole (Test) and Neupro® (Reference) | two treatment periods (4 days) | Using a mixed-effects model adjusted for period and sequence effects, with subject as a random effect |
| Secondary | Proportion of participants achieving more than 90% adherence at 4, 8, 12 and 24 hours at each period as assessed by the investigator/designee as per modified EMA scale for adhesion. | two treatment periods (4 days) | |
| Secondary | Adjusted Mean adherence percentage at each assessment time (4, 8, 12 and 24 hours). | two treatment periods (4 days) | |
| Secondary | Proportion of participants with a meaningful degree of detachment (more than half of the patch lifting off the skin or falling off) at 4, 8, 12 and 24 hours. | two treatment periods (4 days) | |
| Secondary | Number of patches that are completely detached at 4, 8, 12 and 24 hours. | two treatment periods (4 days) | |
| Secondary | Number of participants with cold flow in each treatment period (Cold flow is defined as dark ring formed around the patch). | two treatment periods (4 days) | |
| Secondary | Number of participants with patch movement/displacement in each treatment period. | two treatment periods (4 days) | |
| Secondary | Number of participants with patch wrinkling in each treatment period. | two treatment periods (4 days) | |
| Secondary | Number of participants with patch residue formation in each treatment period (Patch residue formation is assessed at patch application on the release liner and at patch removal on the skin). | two treatment periods (4 days) | |
| Secondary | % of patients reporting ease or difficulty in patch application and removal. | two treatment periods (4 days) |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07015346
GET https://conductscience.org/api/trials/v1/NCT07015346/registered